Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$1.50 USD
-0.05 (-3.25%)
Updated May 20, 2024 03:48 PM ET
After-Market: $1.50 0.00 (0.03%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADIL 1.50 -0.05(-3.25%)
Will ADIL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADIL
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adial (ADIL) Shares Up 43% in the Past Week: Here's Why
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ADIL
Adial Pharmaceuticals reports Q1 results
ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals expects cash to fund operations into Q1 of 2025
Adial Pharmaceuticals Finalizes Separation Agreement with Dr. Johnson